Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ILS-920 Administered Intravenously To Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2010
At a glance
- Drugs ILS 920 (Primary)
- Indications Stroke
- Focus Adverse reactions
- 04 Feb 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 04 Feb 2010 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 04 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.